Mizuho views the selloff yesterday in shares of Corvus Pharmaceuticals (CRVS) following the Phase 1 data for soquelitinib in atopic dermatitis as “way overdone.” Mizuho found the data “promising “on both efficacy and safety. At this stage, soquelitini appears competitive to the currently approved oral and injected drugs, the analyst tells investors in a research note. It keep an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVS:
- Corvus Pharmaceuticals Reports Promising Phase 1 Data and Financial Boost
- Corvus Pharmaceuticals announce interim data from Phase 1 trial of soquelitinib
- Closing Bell Movers: Heico slips 7% after Q4 results
- Corvus publishes data on potential of soquelitinib to modulate tumor activity
- Corvus Pharmaceuticals announces preclinical dataon soquelitinib